NCT02923778View on ClinicalTrials.gov

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2019

Primary Completion Date

May 29, 2026

Study Completion Date

May 29, 2026

Conditions
LeiomyosarcomaLiposarcomaSarcoma G2Sarcoma G3Soft Tissue SarcomaSoft Tissue Sarcoma of the Trunk and ExtremitiesStage I Soft Tissue Sarcoma AJCC v7Stage II Soft Tissue Sarcoma AJCC v7Undifferentiated Pleomorphic Sarcoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

RADIATION

Radiation Therapy

Undergo radiation therapy

BIOLOGICAL

Talimogene Laherparepvec

Given IT or via intralesional injection

Trial Locations (17)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

23298

VCU Massey Comprehensive Cancer Center, Richmond

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic in Rochester, Rochester

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

77030

M D Anderson Cancer Center, Houston

85054

Mayo Clinic Hospital in Arizona, Phoenix

91010

City of Hope Comprehensive Cancer Center, Duarte

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

32224-9980

Mayo Clinic in Florida, Jacksonville

03756

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH